[Recent advances on the use of erythropoietin in oncology].

Date publication

mai 2006

Auteurs

Membres identifiés du Cancéropôle Est :
Dr SPAETH Dominique

Tous les auteurs :
Spaeth D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/16777627

Résumé

The Standards, Options and Recommendations on the use of erythropoietin in cancer patients are recalled. The recent literature is analysed and allows some further comments to the SOR. Medico-economic aspects, new schedules of administration, extra-hematologic virtues of erythropoietin and its impact on cancer outcomes are debated.

Référence

Bull Cancer. 2006 May 1;93(5):489-93.